

Uricofell[®]

febuxostat

Scored F.C. tablets:

- 40 mg
- 80 mg



- ✓ درمان نقرس
- ✓ کنترل نقرس
- ✓ کاهش اسید اوریک خون
- ✓ کنترل مزمن هایپر اوریمی خون در بیماران نقرسی

یوریکوفل[®]

Pharmacologic Category:

Anti-Gout Agents, Xanthine oxidase inhibitor

Mechanism of Action:

febuxostat blocks the metabolism of hypoxanthine and xanthine (oxypurines) to uric acid.

Indications:

For the chronic management of hyperuricemia in patients with gout (gouty arthritis).

Contraindications:

Febuxostat is contraindicated in patients being treated with *Azathioprine* or *Mercaptopurine*

Pharmacokinetics:

Absorption: Approximately 49% of an orally administered dose

Distribution: Plasma protein binding is approximately 99.2% (primarily to albumin)

Metabolism: by conjugation via uridine diphosphate glucuronosyltransferase (UDPGT) enzyme system and oxidation via the cytochrome P450 (CYP) system

Elimination: by both hepatic and renal pathways. Half-life: 5 to 8 hours

Administration:

The recommended dosage is 40 mg or 80 mg once daily.

The recommended starting dose is 40 mg once daily.

For patients who do not achieve a serum uric acid (sUA) less than 6 mg/dl after two weeks, the recommended dosage is 80 mg once daily.

Adverse effects:

Liver function abnormalities, headache, nausea, dizziness, rash, arthralgia.

Warning:

Because of the increased risk of cardiovascular mortality, febuxostat should use with caution in patients with a history of stroke or myocardial infarction, preexisting cardiac disease, or other cardiac risk factors.

Reference:

www.pdr.net

www.medicines.org.uk

www.rxlist.com

www.accessdata.fda.gov